Our patented novel Ensilication technology uses silica to create an individually tailored protective nanoshell around vaccines, antibodies and enzymes to prevent degradation, which can lead to spoilage. Once applied, the material can be stored and transported without the need for cold chain infrastructure, improving global access to medicines and reducing wastage and emissions across the pharmaceutical supply chain. Ensilication preserves the integrity of a wide variety of biomolecules and proteins, not only protecting against environmental degradation, but also making possible the development of more convenient administration such as subcutaneous and oral delivery for both humans and animals. We are actively looking for partners to work with us in developing ensilicated products, free from cold chain dependence. Please don’t hesitate to contact us if you’re interested in finding out more about us, and how our technology may benefit your products.
| Website | http://www.ensilitech.com |
| Employees | 18 (14 on RocketReach) |
| Founded | 2022 |
| Industry | Biotechnology Research |
| Keywords | Vaccine Technology, Nanoscale Materials, Biotechnology, Pharmaceutical Technology, Drug Delivery, Vaccine Storage, Vaccine Transport, Vaccine Development, Protective Coatings, Nanotechnology Applications, Material Science, Pharmaceutical Research, Biomedical Engineering, Vaccine Efficacy |
| Competitors | Intel Corporation, NVIDIA, Broadcom, Texas Instruments, Analog Devices, Microchip Technology Inc., Lattice Semiconductor, Xilinx, Altera, Cypress Semiconductors +54 more (view full list) |
Looking for a particular EnsiliTech employee's phone or email?
Asel Sartbaeva is the Co-founder and CEO of EnsiliTech.
14 people are employed at EnsiliTech.
EnsiliTech is based in Bristol, England.